Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 6/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 10/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485872 | 0.91 | CACNA1B (0.47) | UBE2MDCUN1D1CACNA1BGAAHPGD | |
| SCHEMBL3485549 | 0.85 | UBE2M (0.48) | UBE2MDCUN1D1CACNA1BGAALMNA | |
| SCHEMBL8082563 | 0.83 | CACNA1B (0.48) | UBE2MDCUN1D1CACNA1BGAAHPGD | |
| SCHEMBL3762464 | 0.83 | CACNA1B (0.46) | UBE2MDCUN1D1CACNA1BGAAHPGD | |
| SCHEMBL3484838 | 0.82 | NPSR1 (0.53) | UBE2MDCUN1D1CACNA1BLMNASMN1; SMN2 | |
| SCHEMBL8083318 | 0.82 | CACNA1B (0.46) | UBE2MDCUN1D1CACNA1BGAAHPGD | |
| SCHEMBL13002406 | 0.81 | CACNA1B (0.51) | UBE2MDCUN1D1CACNA1BGAAHPGD | |
| SCHEMBL3485159 | 0.80 | CACNA1B (0.50) | CACNA1BGAAHPGDCACNA1CNR1I2 | |
| SCHEMBL3485824 | 0.79 | ALDH1A1 (0.52) | UBE2MDCUN1D1CACNA1BLMNASMN1; SMN2 | |
| SCHEMBL3485265 | 0.79 | ALDH1A1 (0.47) | UBE2MDCUN1D1CACNA1BGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | claimed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | claimed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | CACNA1A, CACNA1E, CACNA1B | UBE2M 4024/4885DCUN1D1 3781/4885CACNA1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.